IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results

Iradimed posts record Q3 revenue and earnings, raises near-term guidance, and declares a dividend.

What the company is saying

Iradimed reports record third-quarter revenue of $24.2 million, emphasizing the impact of the 3870 MR IV pump launch and increased operational efficiency. The company highlights a 14% year-over-year revenue increase and a 17% rise in net income to $6.5 million for the quarter, with diluted EPS up 17% to $0.51. Management, led by President and CEO Roger Susi, frames the narrative around strong product adoption, citing record bookings and a 45% year-over-year increase in domestic pump channels, though without providing supporting figures. Over 70% of pump bookings were for the 'quad stack' configuration, which the company claims doubles pump channels per MRI. The tone is confident, projecting fourth-quarter revenue of $25.0 million to $26.5 million and a $100.0 million revenue run rate, with updated full-year guidance for revenue of $91.6 million to $93.1 million and GAAP EPS of $1.90 to $1.94. The board declared a $0.20 per share dividend, reinforcing a message of financial strength and shareholder return.

What the data suggests

The disclosed figures show clear financial momentum: Q3 revenue rose 14% year-over-year to $24.2 million, net income increased 17% to $6.5 million, and diluted EPS climbed to $0.51 from $0.43. Non-GAAP net income was $7.1 million, up 17%, and non-GAAP EPS was $0.55, up from $0.47. For the nine months ended September 30, 2026, revenue reached $66.6 million, up 9%, with net income at $17.5 million and EPS at $1.37, both showing similar growth rates. Cash flow from operations was $7.0 million for the quarter and $21.2 million year-to-date, up 12% from the prior year. Gross margin was 76% for both the quarter and year-to-date, slightly down from the previous year. The company revised its full-year revenue guidance to $91.6 million to $93.1 million, narrowing the range and lowering the upper end, and similarly tightened EPS guidance. While financial disclosures are detailed and transparent, operational claims about bookings and product configuration adoption are not quantified. The evidence supports the financial growth narrative but does not substantiate all operational superlatives.

Analysis

The announcement is generally positive and well-supported by realised financial results: record quarterly revenue, net income, EPS, and cash flow are all disclosed with clear year-over-year growth. Profitability metrics (net income, EPS, gross margin, cash flow) are provided alongside revenue, satisfying the requirements for a strong_positive signal. However, some operational claims—such as record bookings, a 45% increase in domestic pump channels, and over 70% 'quad stack' configuration adoption—are not backed by numerical evidence, which slightly inflates the narrative. The forward-looking elements (Q4 and full-year guidance) are proportionate and near-term, not aspirational or long-dated. There is no indication of a large capital outlay with deferred returns. The overall tone is upbeat but mostly justified by the disclosed results, with only moderate hype present in the unsupported operational superlatives.

Risk flags

• ●Operational claims about record bookings and product adoption lack supporting numerical data, making it difficult to independently verify the scale of these achievements. This raises questions about the magnitude and sustainability of the operational momentum.
• ●Gross margin declined year-over-year from 78% to 76% for the quarter, indicating some cost pressure or product mix shift that could affect future profitability if the trend continues.
• ●The revised full-year guidance narrows and lowers the upper end of revenue and EPS expectations, suggesting management sees less upside than previously anticipated. This could signal a more cautious outlook or emerging headwinds.
• ●Domestic sales as a percentage of total revenue declined from 85% to 82% year-over-year, which may reflect increased international exposure but could also introduce currency or market-specific risks.
• ●Stock-based compensation expense remains a recurring adjustment in non-GAAP results ($0.6 million for Q3, $1.8 million year-to-date), which investors should monitor for potential dilution or impact on reported profitability.

Bottom line

Iradimed's Q3 results confirm strong financial performance, with record revenue, net income, and cash flow, and a dividend reinforcing shareholder returns. The company's narrative of operational strength is partially supported by the financials but lacks detailed bookings or adoption data to fully validate claims of record product momentum. Guidance for Q4 and the full year is positive but slightly more conservative than before, reflecting either prudent management or a recognition of potential headwinds. Gross margin compression and a shift in revenue mix warrant monitoring, as does the ongoing impact of stock-based compensation. Investors should focus on whether future disclosures provide more granular operational metrics and whether the company can sustain its growth trajectory into 2027. The most important takeaway is that Iradimed is delivering on its financial promises, but the operational story would benefit from greater transparency.

Announcement summary

(NASDAQ: IRMD) Iradimed Corporation announced financial results for the three and nine months ended September 30, 2026. The company reported record revenue of $24.2 million for the third quarter of 2026, driven by the successful launch of the 3870 MR IV pump. Gross margin improved sequentially, and quarterly bookings set new records, including a record number of monitor units booked and a 45% year-over-year increase in domestic pump channels booked. Over 70% of pump bookings in the quarter were for the 'quad stack' configuration, doubling the pump channels previously available at each MRI. For the fourth quarter of 2026, Iradimed expects revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate, with GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61. The company revised its full-year 2026 guidance to revenue of $91.6 million to $93.1 million, from the previous range of $91.0 million to $96.0 million, and GAAP diluted earnings per share to $1.90 to $1.94 from $1.90 to $2.05, and non-GAAP diluted earnings per share to $2.07 to $2.11 from $2.06 to $2.21. The board of directors declared a regular quarterly cash dividend of $0.20 per share, payable to stockholders of record as of November 13, 2026, with payment on November 27, 2026. For the three months ended September 30, 2026, revenue was $24.2 million, up from $21.2 million in 2025, an increase of $3.0 million or 14%. Net income for the quarter was $6.5 million, up from $5.6 million in 2025, a 17% increase. Earnings per share for the quarter increased by $0.08 or 17% to $0.51 per diluted share, compared to $0.43 in 2025. Non-GAAP net income for the quarter was $7.1 million, up 17% from $6.1 million in 2025, with non-GAAP net income per diluted share at $0.55, up from $0.47. Stock-based compensation expense, net of tax benefit, was $0.6 million for the third quarter of 2026 and $0.5 million for the third quarter of 2025. For the nine months ended September 30, 2026, revenue was $66.6 million, up from $61.1 million in 2025, an increase of $5.5 million or 9%. Net income for the nine months was $17.5 million, up from $16.0 million in 2025, a 9% increase. Earnings per share for the nine months increased by $0.12 or 10% to $1.37 per diluted share, compared to $1.25 in 2025. Non-GAAP net income for the nine months was $19.3 million, up 9% from $17.8 million in 2025, with non-GAAP net income per diluted share at $1.50, up from $1.39. Stock-based compensation expense, net of tax benefit, was $1.8 million for each of the nine-month periods presented. Device revenue for the third quarter of 2026 included $8,687,000 from MRI Compatible IV Infusion Pump Systems, $8,006,000 from MRI Compatible Patient Vital Signs Monitoring Systems, and $483,000 from Ferro Magnetic Detection Systems. Total device revenue was $17,176,000. Amortization of extended maintenance agreements was $801,000, disposables revenue was $4,981,000, and services and other revenue was $1,245,000, for total revenue of $24,203,000. For the nine months ended September 30, 2026, device revenue included $22,779,000 from MRI Compatible IV Infusion Pump Systems, $21,778,000 from MRI Compatible Patient Vital Signs Monitoring Systems, and $1,861,000 from Ferro Magnetic Detection Systems, for total device revenue of $46,418,000. Amortization of extended maintenance agreements was $2,218,000, disposables revenue was $14,659,000, and services and other revenue was $3,353,000, for total revenue of $66,648,000. Domestic sales were 82% of total revenue for both the three and nine months ended September 30, 2026, compared to 85% for the same periods in 2025. Gross profit margin was 76% for the three months ended September 30, 2026, compared to 78% in 2025, and 76% for the nine months ended September 30, 2026, compared to 77% in 2025. Cash flow from operations was $7.0 million for the three months ended September 30, 2026, consistent with the same period in 2025. For the nine months ended September 30, 2026, cash flow from operations was $21.2 million, up from $19.0 million in 2025, a 12% increase. The company expects stock-based compensation expense, net of tax, to be approximately $2.5 million for the full year and $0.6 million for the third quarter of 2026. The company scheduled a conference call for October 30, 2026, at 11:00 a.m. Eastern Time to discuss these results.

Disagree with this article?